Polycythemia vera risk factors: Difference between revisions
(Mahshid) |
Shyam Patel (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Polycythemia vera}} | {{Polycythemia vera}} | ||
{{CMG}}{{AE}}{{MJK}} | {{CMG}}{{AE}}{{MJK}} {{shyam}} | ||
==Overview== | ==Overview== | ||
Common risk factors in the development of polycythemia vera are a positive history of thrombotic event and old age ( 65 year old and older).<ref name="pmid25377561">{{cite journal| author=Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F et al.| title=In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. | journal=Blood | year= 2014 | volume= 124 | issue= 19 | pages= 3021-3 | pmid=25377561 | doi=10.1182/blood-2014-07-591610 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25377561 }} </ref> | Common risk factors in the development of polycythemia vera are a positive history of thrombotic event and old age ( 65 year old and older).<ref name="pmid25377561">{{cite journal| author=Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F et al.| title=In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. | journal=Blood | year= 2014 | volume= 124 | issue= 19 | pages= 3021-3 | pmid=25377561 | doi=10.1182/blood-2014-07-591610 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25377561 }} </ref> | ||
| Line 9: | Line 9: | ||
* A positive history of thrombotic event | * A positive history of thrombotic event | ||
* Old age ( 65 year old and older) | * Old age ( 65 year old and older) | ||
The risk factors for the development of [[myelofibrosis]] from polycythemia vera include: | |||
*Increased age | |||
*Leukocytosis | |||
*High variant allele frequency of the JAK2 mutation (high allele burden) | |||
*Thrombocytosis | |||
*Splenomegaly | |||
The risk factors for the development of [[acute myeloid leukemia]] from polycythemia vera include: | |||
*Increased age | |||
*Leukocytosis | |||
*Splenomegaly | |||
*Abnormal karyotype | |||
==References== | ==References== | ||
Revision as of 01:30, 21 January 2018
|
Polycythemia vera Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Polycythemia vera risk factors On the Web |
|
American Roentgen Ray Society Images of Polycythemia vera risk factors |
|
Risk calculators and risk factors for Polycythemia vera risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]
Overview
Common risk factors in the development of polycythemia vera are a positive history of thrombotic event and old age ( 65 year old and older).[1]
Common Risk Factors
Common risk factors in the development of polycythemia vera are:[1]
- A positive history of thrombotic event
- Old age ( 65 year old and older)
The risk factors for the development of myelofibrosis from polycythemia vera include:
- Increased age
- Leukocytosis
- High variant allele frequency of the JAK2 mutation (high allele burden)
- Thrombocytosis
- Splenomegaly
The risk factors for the development of acute myeloid leukemia from polycythemia vera include:
- Increased age
- Leukocytosis
- Splenomegaly
- Abnormal karyotype
References
- ↑ 1.0 1.1 Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F; et al. (2014). "In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology". Blood. 124 (19): 3021–3. doi:10.1182/blood-2014-07-591610. PMID 25377561.